Document:

Form of 7.00% Senior Notes due 2040.

 Exhibit 4.2 

LINCOLN NATIONAL CORPORATION 

7.00% Senior Note due 2040 
  

					
	 [Registered]
	 		  	CUSIP 534187BA6
		 		  	ISIN US534187BA67
	 No. R-1
	 		  	  U.S. $

  

					
		  	 UNLESS THIS SECURITY IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”), TO THE COMPANY
(AS DEFINED BELOW) OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY SECURITY ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS
MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF,
CEDE & CO., HAS AN INTEREST HEREIN.
	  	
			
		  	 THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF DTC OR A NOMINEE THEREOF. THIS
SECURITY MAY NOT BE EXCHANGED IN WHOLE OR IN PART FOR A SECURITY REGISTERED, AND NO TRANSFER OF THIS SECURITY IN WHOLE OR IN PART MAY BE REGISTERED, IN THE NAME OF ANY PERSON OTHER THAN DTC OR SUCH NOMINEE, EXCEPT IN THE LIMITED CIRCUMSTANCES
DESCRIBED IN THE INDENTURE.
	  	

 Lincoln National Corporation, a corporation organized and existing under the laws of the State of
Indiana (hereinafter called the “Company”, which term includes any successor corporation under the Indenture hereinafter referred to), for value received, hereby promises to pay to
            , or registered assigns, the principal sum of                     
($        ) on June 15, 2040 and to pay interest thereon from June 18, 2010 or from the most recent interest payment date to which interest has

 
been paid or duly provided for, semi-annually in arrears on June 15 and December 15, in each year, commencing on December 15, 2010 (each, an “Interest Payment Date”), at
the rate of 7.00% per annum. The period beginning on June 18, 2010 and ending on but excluding the first Interest Payment Date and each successive period beginning on and including an Interest Payment Date and ending on but excluding the
next succeeding Interest Payment Date is herein called an “Interest Period”. If any Interest Payment Date falls on a day which is not a Business Day, such Interest Payment Date shall be postponed to the next succeeding Business Day. If
June 15 or December 15 of any year is not a Business Day (with the consequence that the related interest payment shall be made on the next succeeding Business Day, which shall be the relevant Interest Payment Date as set forth above), such
payment shall be made on such Interest Payment Date in the amount that would otherwise have been due on June 15 or December 15 and no interest on such payment shall accrue for the period from and after June 15 or December 15 to
such postponed Interest Payment Date, and the next succeeding Interest Period shall begin on June 15 or December 15 on which such payment originally would have been made. If June 15, 2040 shall not be a Business Day, payment of the
principal and interest due on that date need not be made on that day but may be made on the next day that is a Business Day with the same force and effect as if made on June 15, 2040, provided that no interest shall accrue for the period from
and after June 15, 2040. The interest so payable and punctually paid or duly provided for on any Interest Payment Date will, as provided in the Indenture, be paid to the person in whose name this Note is registered at the close of business on
June 1 or December 1 (whether or not a Business Day) immediately preceding the Interest Payment Date, as applicable (each respectively a “Record Date”), subject to certain exceptions as provided in the Indenture. Payment of the
principal of, and interest on, this Note will be made at the designated office or agency of the Company maintained for such purpose in The City of New York, New York in such coin or currency of the United States of America as at the time of payment
is legal tender for payment of public and private debt or, at the option of the Company, interest so payable may be paid by check to the order of said Holder mailed to his address appearing on the Security Register. Any interest not so punctually
paid or duly provided for shall be payable as provided in the Note. Interest on this Note will be computed on the basis of a 360-day year consisting of twelve 30-day months. 

Reference is hereby made to the further provisions of this Note set forth on the reverse hereof, which further provisions shall for all
purposes have the same effect as if set forth at this place. 
 Unless the certificate of authentication hereon has been
executed by the Trustee by manual signature, this Note shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. 
  

 -2- 

 IN WITNESS WHEREOF, Lincoln National Corporation has caused this instrument to be duly
executed under its corporate seal. 
  

			
	LINCOLN NATIONAL CORPORATION
		
	By:	 	  

	Name:	 	
	Title:	 	
		
	By:	 	  

	Name:	 	
	Title:	 	

  

			
	Attest:	 	  

	Name:	 	
	Title:	 	

 Dated: June 18, 2010 

 Dated: June 18, 2010 

Trustee’s Certificate of Authentication 

This is one of the Securities of the series designated herein and referred to in the within-mentioned Indenture. 

 

			
	 THE BANK OF NEW YORK MELLON, as

    Trustee

		
	By:	 	  

		 	Authorized Signatory

 [Reverse of Note] 

LINCOLN NATIONAL CORPORATION 

7.00% Senior Note due 2040 

This Note is one of a duly authorized issue of Securities of the Company of a series hereinafter specified, all issued and to be issued
under the Senior Indenture, dated as of March 10, 2009 (hereinafter the “Indenture”), between the Company and The Bank of New York Mellon, as Trustee (hereinafter the “Trustee”, which term includes any successor Trustee
under the Indenture), to which Indenture and all indentures supplemental thereto reference is hereby made for a statement of the respective rights, limitations of rights, duties and immunities thereunder of the Company, the Trustee and the Holder of
the Securities and the terms upon which the Securities are, and are to be, authenticated and delivered. The Securities may be issued in one or more series, the terms of which different series may vary as provided in the Indenture. This Note is one
of a series of the Securities of the Company designated as its 7.00% Senior Notes due 2040 (herein called the “Notes”), limited initially in aggregate principal amount to $        , except as
otherwise provided in the Indenture. The Notes of this series are issuable in registered form only in minimum denominations of $2,000 and integral multiples of $1,000 in excess thereof. 

All terms used in this Note that are defined in the Indenture shall have the meanings assigned to them in the Indenture. 

The Notes are redeemable, in whole or in part, at the option of the Company, at any time or from time to time, upon mailed notice to the
registered address of each Holder of the Notes at least 30 days but not more than 60 days prior to the redemption. The redemption price will be the greater of (i) 100% of the principal amount of the Notes to be redeemed and (ii) the
make-whole amount, plus in each case accrued and unpaid interest to the date of redemption. “Make-whole amount” means the sum of the present values of the remaining scheduled payments on the Notes, discounted to the date of redemption on a
semi-annual basis (assuming a 360-day year consisting of twelve 30-day months), at a rate equal to the sum of the applicable treasury rate plus 45 basis points. 

“Comparable treasury issue” means the U.S. Treasury security selected by a reference treasury dealer as having an actual or
interpolated maturity comparable to the remaining term of the Notes called for redemption, that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities with
a term comparable to such period. 
 “Comparable treasury price” means, with respect to a redemption date,
(1) the average of five reference treasury dealer quotations for such redemption date, after excluding the highest and lowest reference treasury dealer quotations, or (2) if the quotation agent obtains fewer than five such reference
treasury dealer quotations, the average of all such quotations. 
  

 -5- 

 “Quotation agent” means the entity appointed by the Company, which in any case
shall not be the Trustee, to determine the make-whole amount. 
 “Reference treasury dealer” means (1) J.P.
Morgan Securities Inc. and (2) any additional primary U.S. government securities dealers, including dealers outside New York City (each, a “primary treasury dealer”) selected by the Company and their successors, provided, however,
that if any of them ceases to be a primary treasury dealer the Company will substitute another primary treasury dealer. 

“Reference treasury dealer quotations” means, with respect to each reference treasury dealer and any redemption date, the
average, as determined by the quotation agent, of the bid and ask prices for the comparable treasury issue (expressed in each case as a percentage of its principal amount) quoted in writing to the quotation agent at 5:00 p.m., New York City time, on
the third business day preceding such redemption date. 
 “Remaining scheduled payments” means the remaining
scheduled payments of principal and interest on the Notes called for redemption that would be due after the related redemption date but for that redemption. If that redemption date is not an Interest Payment Date with respect to the Notes called for
redemption, the amount of the next succeeding scheduled interest payment on such Notes will be reduced by the amount of interest accrued to such redemption date. 

“Treasury rate” means, with respect to any redemption date, the rate per annum equal to the semi-annual equivalent yield to
maturity (computed as of the third Business Day immediately preceding that redemption date) of the comparable treasury issue, assuming a price for the comparable treasury issue (expressed as a percentage of its principal amount) equal to the
comparable treasury price for that redemption date. 
 The Company will prepare and mail a notice of redemption to each Holder
of Notes to be redeemed by first-class mail at least 30 and not more than 60 days prior to the date fixed for redemption. On and after a redemption date, interest will cease to accrue on the Notes called for redemption (unless the Company defaults
in the payment of the redemption price and accrued interest). On or before a redemption date, the Company will deposit with a paying agent (or the Trustee) money sufficient to pay the redemption price of and accrued interest on the Notes to be
redeemed on that date. If less than all of the Notes are to be redeemed, the Notes to be redeemed shall be selected by the Trustee pro rata or by lot or by a method the Trustee deems to be fair and appropriate. 

The Notes are not entitled to any sinking fund. If an Event of Default shall occur with respect to the Notes, the principal of the Notes
may be declared due and payable in the manner and with the effect provided in the Indenture. 
  

 -6- 

 The Indenture contains provisions for defeasance at any time of the Notes, upon which the
Company, at its option, shall be deemed to have been discharged from its obligations with respect to the Notes or shall cease to be under any obligation to comply with certain restrictive covenants of the Indenture. 

Subject to certain exceptions, the Indenture or the Notes may be amended or supplemented with the consent of the Holders of at least a
majority in principal amount of the Outstanding Securities affected by such amendment or supplement voting as one class. Without the consent of any Holder, the Company and the Trustee may amend or supplement the Indenture or the Notes to, among
other things, cure any ambiguity, defect or inconsistency. Subject to certain exceptions, any past default or Event of Default may be waived by the Holders of at least a majority in principal amount of the Outstanding Securities of any series
affected on behalf of the Holders of the Securities of that series or the Holders of at least a majority in principal amount of all the Outstanding Securities voting as one class. After the amendment or supplement is effective, any such consent or
waiver by the Holder of this Note shall be conclusive and binding upon such Holder and upon all future Holders of this Note and of any Note issued upon the transfer hereof or in exchange hereunder or in lieu hereof whether or not notation of such
consent or waiver is made upon this Note or upon any Note issued upon the transfer hereof or in exchange herefor or in lieu hereof. 

No reference herein to the Indenture and no provision of this Note or of the Indenture shall alter or impair the obligation of the
Company, which is absolute and unconditional, to pay the principal of, and interest on, this Note at the times, place, and rate, and in the coin or currency, herein prescribed. 

As provided in the Indenture and subject to certain limitations therein set forth, this Note is transferable on the Security Register of
the Company, upon surrender of this Note for transfer at the office or agency of the Company in The City of New York, New York, duly endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Company and the Security
Registrar, duly executed by the Holder hereof or his attorney duly authorized in writing, and thereupon one or more new Notes, of authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or
transferees. 
 As provided in the Indenture and subject to certain limitations therein set forth, this Note is exchangeable
for a like aggregate principal amount of Notes of different authorized denominations as requested by the Holder surrendering the same. 

No service charge will be made for any such transfer or exchange, but the Company may require payment of a sum sufficient to cover any
tax or other governmental charge payable in connection therewith. 
 The Company, the Trustee and any agent of the Company or
the Trustee may treat the person in whose name this Note is registered as the owner hereof for the 
  

 -7- 

 
purpose of receiving payment as herein provided and for all other purposes whether or not this Note be overdue, and neither the Company, the Trustee nor any agent shall be affected by notice to
the contrary. 
 No recourse shall be had for the payment of the principal of, or the interest on, this Note or for any claim
based hereon or otherwise in any manner in respect hereof, or in respect of the Indenture, against any incorporator, shareholder, officer or director, as such, past, present or future, of the Company or of any predecessor or, except as provided in
the Indenture, successor corporation, whether by virtue of any constitutional provision or statute or rule of law, or by the enforcement of any assessment or penalty or in any other manner, all such liability being expressly waived and released by
the acceptance hereof and as part of the consideration for the issue hereof. 
  

 -8-Form of Distribution Agreement

 Exhibit 10.1 

FORM OF DISTRIBUTION AGREEMENT 

Signed at [            ], on
[            ] 20[    ]. 
  

	1.	Parties: 

  

	 	1.1	Nilimedix Ltd., based in 3 HaSadna Street, TIRAT HaKARMEL, ISRAEL (Including G-Sense Ltd. And Medx-set Ltd), represented by its VP Marketing and Business Development,
hereinafter “Nilimedix”; 

 And 
  

	 	1.2	[            ] hereinafter the “Distributor”; 

 

	2.	Whereas: 

  

	 	2.1	Parties have agreed that Distributor will purchase and resell products as an exclusive and independent dealer for the territory of
[            ], hereinafter the “Territory” 

  

	 	2.2	Parties herewith want to regulate their mutual legal relationship further. 

 

	 	2.3	This agreement will relate to distribution of Products as detailed in Appendix I and will be empowered only subject to the execution of an initial purchase
specified in Appendix I herewith. 

 HAVE AGREED AS FOLLOWS: 

 

	3.	Term 

  

	 	3.1	The term of this agreement shall commence on the day signed and upon full payment for an initial order as in attached appendix I and shall be in effect for
[    ] months thereafter. Without any written notice, the term shall be renewed annually, unless a party notifies the other party in writing at least [    ] months in advance of its
intention not to renew the agreement 

  

	 	3.2	Previous agreements between Distributor and Nilimedix will become void upon signing this agreement. 

 

	4.	Exclusivity 

  

	 	4.1	Nilimedix will not grant any other party a right to sell Nilimedix’ Products in the Territory 

 

	 	4.2	Distributor refrains from trading or representing products which may compete with Nilimedix’s products in the territory, unless otherwise agreed upon in
writing by Nilimedix. 

	 	4.3	Both parties agree on a yearly target as described in appendix I or as mutually agreed in writing. Failure to reach the target without a cause accepted by
Nilimedix, may result in loss of exclusivity or termination of the contract. Target will be re-negotiated and mutually agreed upon on a yearly basis. Unless otherwise agreed upon, such targets will be at least equal to the target or the,
purchase volume of the previous year, whatever is higher. 

  

	5.	Territory 

  

	 	5.1	The territory assigned to Distributor is the [            ]. 

 

	 	5.2	Distributor agrees not to solicit sales of products outside the territory. 

 

	6.	Products 

  

	 	6.1	Nilimedix commits to sell for resale and distribution in the territory products specified on Appendix I. 

 

	 	6.2	Nilimedix will favourably consider including future products, when available, in this distributor agreement, subject to satisfying performance with existing
product line. 

  

	7.	Orders 

  

	 	7.1	Purchase orders will be placed in writing. 

  

	 	7.2	Nilimedix shall maintain the right to reject or alter any purchase order. In writing within seven working days from receiving of said order, any such rejection
and/or alterations shall not cause any harm to Nilimedix nor shall it entitle the Distributor to any relief. 

  

	 	7.3	Repeated breach of this item of the agreement can be considered as gross violation of the terms of this agreement 

 

	 	7.4	No purchase order shall be binding unless and until Nilimedix accepts it in writing, or unless and until delivery to the Distributor takes place.

  

	 	7.5	Purchase orders will not include any terms or conditions contradicting the terms specified In this Agreement — in case of contradiction — the PO will remain
valid but the Agreement terms will prevail. 

  

	8.	Prices and payment terms 

  

	 	8.1	Prices specified in Appendix 1 to this agreement may be adjusted from time to time by Nilimedix with 60 day advanced notice. 

 

	 	8.2	Terms of payment shall be by wire transfer to the Nilimedix bank account: 

 

			
	[            ]	  	Account Number: [            ]
		
	Swift Code/ BIC / TID — [            ]	  	
		
	Routing Number: [            ]	  	
		
	[            ]	  	

  

 - 2 - 

	 	8.3	Distributor shall be in default without further notice if payment is not received on time. 

 

	 	8.4	Unpaid invoice shall accrue daily Interest at a rate of [    ]% per month. The Distributor shall also indemnify Nilimedix for any and
all expenses incurred by Nilimedix in lieu failed and/or late payment without limitation such expenses shall include among others attorney’s fees. Without derogating from the aforesaid any failure of payment and/or retardation of payment shall
entitle Nilimedix to agree upon compensation equal to [    ]% of the actual sum unpaid and/or which is not paid on time, without the necessity of proving actual damages. 

 

	 	8.5	Distributor shall be responsible for paying all taxes, custom duties, assessments, and similar governmental charges associated with the sale of products (such as sales,
VAT, use of similar taxes). 

  

	9.	Freight 

 All shipments
shall be [    ]. 
  

	10.	Trademarks and commercial names 

  

	 	10.1	Distributor recognises that any trademarks, trade names, designs, copyrights and other proprietary rights, used on or embodied in the products (Proprietary
Rights) shall remain the exclusive property of Nilimedix. Upon termination of this agreement for any cause, Distributor shall cease using in any way the Nilimedix name or any of its product names or any other proprietary rights
or any material similar thereto. 

  

	 	10.2	Nilimedix grants Distributor the right of use of related trademarks and product names for products listed in appendix 1 in the territory.

  

	11.	Support 

  

	 	11.1	Distributor will provide an acceptable level of product-support, without limitation, technical and educational support service at all times for answering
questions or encountering problems on an immediate basis. 

  

	 	11.2	Distributor will take part in trainings, workshops, etc. provided by Nilimedix. 

 

	 	11.3	Nilimedix may provide marketing and training material, upon its sole discretion to assist Distributors marketing activities, such as seminars, exhibitions and
conferences. 

  

 - 3 - 

	12.	Prohibitions 

  

	 	12.1	Distributor agrees not to solicit sales of any product to customers outside the designated Territory, whether via mail order, via the Internet or otherwise.
Nilimedix however agrees not to knowingly sell to any other company or individual in Distributor’s territory even if such company buys through other office. 

 

	13.	Warranty and Repair 

  

	 	13.1	Subject to the terms of article 19 herein, defective products can be returned to Nilimedix during warranty period of such product after a Return Material
Authorisation (RMA) number is assigned by Nilimedix. 

  

	 	13.2	Subject to article 13.3 freight charges for returned defective Products would be borne by Nilimedix 

 

	 	13.3	In case a product is defective the Distributor may return such defective products to Nilimedix subject that returned defective products shall only be accepted when, a
serial numbers inventory and a short description of the failure resulting in returning the product accompany the shipment. 

  

	 	13.4	Distributor will follow Nilimedix procedures for Warranty Repair and Refurbishment as those will be updated from time to time. 

 

	14.	Confidentiality 

  

	 	14.1	Parties agree to hold in, trust and confidence the contents, terms and conditions of this agreement and agree not to disclose such to any third party.

  

	 	14.2	Distributor agrees not to use or disclose to any third party without prior written consent by Nilimedix any information that may be disclosed to Distributor
concerning Nilimedix or its products (proposed new products, pricing, business plans, customers, etc.) and vice versa, unless such information had previously been in the public domain. 

 

	15.	Professional handling and Traceability 

  

	 	15.1	Distributor undertakes to devotedly and faithfully practice its assignment to promote and enhance the scope of Nilimedix products sales in the Territory.

  

	 	15.2	Distributor undertakes to do its utmost in order to assure that Nilimedix products are only forwarded to suitable users who have been identified as
capable of properly handling the device and only after successfully passing complete comprehensive user training by a competent tutor. 

  

	 	15.3	Distributor undertakes to manage a support structure capable of educating end-users and providing them on-going follow-up customer service.

  

 - 4 - 

	 	15.4	Distributor will be responsible to perform any local distributor activities dictated as a result of any regulatory requirement including but not limited to the
CE or the MDD (Medical Device Directive). 

  

	 	15.5	Distributor undertakes to fulfill all legal and regulatory requirements in power within the distribution area and promptly update Nilimedix on any
additional legislation or obligation concerning its products. 

  

	 	15.6	Distributor shall follow all concerned regulatory requirements, including users’ database, traceability or product recall. 

 

	 	15.7	Distributor will properly administer database of end-users and product serial numbers for possible traceability. 

 

	 	15.8	Such database list will be made available upon request to Nilimedix that will keep concerned customer information strictly confidential and will refrain from
contacting such customer unless mutually agreed otherwise. 

  

	16.	Force Majeure 

  

	 	16.1	Neither party shall be liable if the performance of this agreement or if any obligation hereunder (except of due payments) is prevented, restricted or interfered with
by reason of fire or other casualty or accident, strikes or labour disputes, inability to procure raw materials, power or supplies, hurricanes, earthquakes, floods, or other acts of God, war or other causes beyond the reasonable control of either
party. 

  

	 	16.2	In the case of force majeure, Nilimedix has the right to change any order in such a way that it can be fulfilled. 

 

	17.	Liability 

  

	 	17.1	Nilimedix will not be held liable for damages of any kind (including loss of information, interruption of business, lost profits) not caused by gross negligence
of Nilimedix. 

  

	 	17.2	Distributor agrees to indemnify, defend and hold Nilimedix harmless for any claims, liabilities, actions, demands, losses, settlements amounts, judgments,
damages or expenses (inclusive of attorney’s fees) made against Nilimedix as a result of act or omission (negligence, misrepresentation, error, etcetera) of the Distributor. Nilimedix warrants it owns all rights, patents
etc. of products sold to Distributor. 

  

	18.	Waiver 

  

	 	18.1	Nilimedix will not assume liability for malfunction resulted by customer’s error due to lack of specific training or in case of product made available to a
subject incapable of handling it. 

  

 - 5 - 

	 	18.2	Delay or omission on the part of Nilimedix requiring performance by the other party under this agreement shall not operate as a waiver of any provision, right or
remedy under this agreement. 

  

	 	18.3	If Distributor shall at any time be overdue on payment Nilimedix may delay shipment of products or cancel outstanding orders until Distributor is
current on all payments. 

  

	19.	Product Quality 

  

	 	19.1	Nilimedix undertakes responsibility for the products quality, not including damages incurred to the products due to an act and/or the negligence of the Distributor
and/or anyone on his behalf after their delivery to the Distributor. It is made clear that the responsibly of the Distributor towards Nilimedix shall be responsibility according to any law. 

 

	 	19.2	Subject to article 19.1 above, in the event the Distributor finds that a product is defective then the Distributor may demand that Nilimedix shall replace such product
with no extra charge to the Distributor. 

  

	 	19.3	Nilimedix and Distributor acknowledge that according to regulations the product should be remained sealed until its delivery to end user. The following poses a
difficulty to identify the datum point to such defect thus poses a difficulty to decide which Party is responsible for the defect. Therefore the Distributor undertakes to notify Nilimedix immediately upon receipt of any demand and/or claim and/or
complaint regarding a defective product so that the Parties can decide who caused the defect and so that Nilimedix can undertake the potential defence against such demand and/or claim and/or complaint. 

 

	 	19.4	Without derogating from the obligations of Nilimedix under any law, Nilimedix shall engage in an insurance policy which shall include insurance coverage for any damages
whether body and/or property which may be incurred to a third party due to the use of the products, according to a commonly accepted insurance coverage, such insurance policy shall mention the Distributor as the distributor of the products.

  

	 	19.5	Notwithstanding the aforesaid, upon receiving of the products by the Distributor, the Distributor shall bear sole responsibility for the maintenance and completeness of
the products, including any break and/or damage and/or absence which may be incurred to the products. 

  

	 	19.6	The Distributor shall undertake an insurance policy which shall include coverage for any damages to the products, under a commonly accepted insurance policy, which may
be incurred while the products are in his possession. 

  

	 	19.7	Notwithstanding the aforesaid in article 19.5, in case a hidden defect is discovered in any product which was not been able to be discovered by reasonable examination
at the time the products were delivered to the Distributor, the Distributor may notify Nilimedix of such defect within 36 hours from its discovery, and Nilimedix shall replace such product within reasonable time. 

 

 - 6 - 

	20.	Termination 

  

	 	20.1	Either party may terminate this agreement, by providing written notice of termination to the other party [    ] days prior to the
effective date of termination. 

  

	 	20.2	Nilimedix is entitled to terminate this agreement with immediate effect without further written notice if Distributor is insolvent, a petition in
bankruptcy is filed, in case of liquidation or has made any assignment by operation of law or otherwise for the benefit of creditors. 

  

	21.	Effect of termination 

  

	 	21.1	In case of termination Distributor’s appointment by Nilimedix shall immediately terminate and Distributor will cease using concerned
trademarks and discontinue all representations as the Nilimedix Distributor. 

  

	 	21.2	Distributor will however fully cooperate in the transfer period while maintaining customer support until substitute measures are in place. 

 

	 	21.3	Nilimedix shall be entitled to reject all or part of any orders received from the Distributor. 

 

	 	21.4	Nilimedix shall be entitled to require Distributor’s performance of any outstanding orders notwithstanding the fact that delivery dates for such
orders may extend beyond the effective date of termination. 

  

	 	21.5	Distributor shall submit Nilimedix within 10 days after the effective date of termination, a summary of the number of the respective products owned by
Distributor. Nilimedix shall purchase any of such products from Distributor at prices to be agreed upon between the parties, but in no event greater than the respective prices paid by Distributor for the products. These products should
be in good condition in unopened original packaging. 

 Any termination will be without prejudice to any other remedy or right of
Nilimedix under this agreement. 
  

	22.	Ownership 

  

	 	22.1	Distributor acknowledges that the product, including the structure, sequence and organisation of the products and related documentation are proprietary to
Nilimedix and that Nilimedix retains exclusive ownership of products, documentation and all proprietary rights associated with them. Distributor takes all reasonable measures to protect such Nilimedix proprietary rights
and products, including patents, trademarks, copyrights trade names and secrets. 

  

 - 7 - 

	 	22.2	During the term of this agreement Distributor obtains a non-transferable right to use Nilimedix’s applicable trademarks to promote and market the
Nilimedix products. Distributor will use his best efforts to promote and market the products. 

  

	23.	Ownership Retention 

  

	 	23.1	Nilimedix retains the ownership of all products delivered to the Distributor to secure payment of all amounts due under this agreement. The ownership
shall terminate upon receipt of payment in full of Nilimedix invoices. 

  

	 	23.2	If Distributor fails to pay any amount when due, Nilimedix will have the right to repossess and remove all or any part of the products, that haven’t
been paid for. Any repossession or removal will be without prejudice to any other remedy or rights of Nilimedix under this agreement. 

  

	 	23.3	Furthermore, on Nilimedix’s first request, Nilimedix shall have a right of pledge over the products in possession of Distributor in order to
secure the prompt and full payment of the outstanding invoices. Nilimedix shall register this pledge as appropriate. 

  

	 	23.4	Any legal action of third parties to products mentioned in this article, are to be made known to Nilimedix at once. 

 

	 	23.5	Distributor agrees not to secure products which have not been paid for in full in its possession as collateral for the benefit of third parties.

  

	24.	Law 

  

	 	24.1	The law of the State of Israel shall exclusively be applicable to this agreement. The United Nation Convention on the Contracts for the International Sale of Goods
(1980) is specifically excluded from application to this agreement. 

  

	 	24.2	Any controversy or claim arising between parties out of or relating to this agreement shall be judged only by the District Court of Tel-Aviv, Israel.

  

			
	Date, [            ]	 	
	Place, [            ]	 	
	 Nilimedix by:
	 	Distributor By:
		
	 Name:
 Position:

 
 Signature:
	 	

  

 - 8 - 

 Appendix 1 

Products 
  

															
	 Sr. No.
	  	 Art. No.
	  	 Description
	  	 1st year

annual

commitment*
	  	 Initial

order

(units)
	  	 Distributor

unit

transfer

Price
	  	 Payment Terms
	  	 Remarks

	 1
	  		  		  		  		  		  		  	
	 2
	  		  		  		  		  		  		  	

  

 - 9 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00175-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00175-of-00352.parquet"}]]